Search - tctmd.com

Displaying 1 - 20 of 34

Sort: Relevancy | Date

Presentation TCT 2025

TCT 216: Outcomes based on the completeness of revascularization in patients with three-vessel coronary artery disease: The FAME 3 Trial

Presenter: Hisao Otsuki

October 26, 2025

Presentation TCT 2024

TCT 23: Outcomes After FFR-Guided PCI Compared With CABG in Patients Presenting With Acute Coronary Syndrome: A Pre-Specified Subgroup Analysis of the FAME 3 Trial

Presenter: Kuniaki Takahashi

October 28, 2024

News Conference News TCT 2021

iFR Matches FFR Through 5 Years: iFR-SWEDEHEART

Caitlin E. Cox

November 04, 2021

News Conference News TCT 2021

FAVOR III China Adds Strength to Value of QFR-Guided PCI

L.A. McKeown

November 04, 2021

News Conference News TCT 2021

FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in Three-Vessel CAD

Michael O'Riordan

November 04, 2021

News Opinion Editor's Corner TCT 2021

In-Person and Online: TCT to Showcase Imaging, Valves, DCBs, and More

Shelley Wood

November 01, 2021

News Conference News TCT 2020

Fewer Events and Symptoms With iFR-Optimized PCI, Suggests DEFINE-PCI Trial

Michael O'Riordan

October 17, 2020

News Conference News TCT 2020

FFR Insights Before and After PCI: Fresh Food for Thought

Caitlin E. Cox

October 16, 2020

News Conference News TCT 2020

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Michael O'Riordan

October 14, 2020

News Opinion Off Script TCT 2019

Off Script: PCI of the Future? Let’s Break Down the Border Between Physiology and Anatomy

Kwan S. Lee

October 14, 2019

Presentation TCT 2019

The Case for Functional (Not Anatomic) Complete Revascularization: Preview of FAME 3

Presenter: William Fearon

September 27, 2019

Presentation TCT 2018

PCI for Ischemia Part I: Critical Analysis of the FAME Trials and ORBITA

Presenter: David J. Cohen, Sunil V. Rao, Bernard J. Gersh

September 22, 2018

News Opinion Editor's Corner TCT 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Shelley Wood

November 22, 2017

News Conference News TCT 2017

FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost

L.A. McKeown

November 02, 2017

Presentation TCT 2017

FAME 2: 3-Year Clinical and Cost-effectiveness Outcomes of FFR-Guided PCI in Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, William F. Fearon

November 02, 2017

News Opinion Editor's Corner TCT 2017

Live From Denver: TCT 2017, Day Four

Shelley Wood

November 02, 2017

News Conference News TCT 2017

ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure

Michael O'Riordan

November 02, 2017

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Shelley Wood

October 20, 2017

News Conference News TCT 2015

Trial Results Often Struggle to Keep Pace With Evolving Technology

Nicole Lou

October 13, 2015

Presentation TCT 2015

Physiological Assessment in Multivessel Disease: What Will SYNTAX 2 and FAME 3 Tell Us?

Presenter: Sergio B Baptista, Eric Van Belle, Bernard De Bruyne

October 12, 2015

Advertisement

TCT 216: Outcomes based on the completeness of revascularization in patients with three-vessel coronary artery disease: The FAME 3 Trial

TCT 23: Outcomes After FFR-Guided PCI Compared With CABG in Patients Presenting With Acute Coronary Syndrome: A Pre-Specified Subgroup Analysis of the FAME 3 Trial

iFR Matches FFR Through 5 Years: iFR-SWEDEHEART

FAVOR III China Adds Strength to Value of QFR-Guided PCI

FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in Three-Vessel CAD

In-Person and Online: TCT to Showcase Imaging, Valves, DCBs, and More

Fewer Events and Symptoms With iFR-Optimized PCI, Suggests DEFINE-PCI Trial

FFR Insights Before and After PCI: Fresh Food for Thought

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Off Script: PCI of the Future? Let’s Break Down the Border Between Physiology and Anatomy

The Case for Functional (Not Anatomic) Complete Revascularization: Preview of FAME 3

PCI for Ischemia Part I: Critical Analysis of the FAME Trials and ORBITA

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost

FAME 2: 3-Year Clinical and Cost-effectiveness Outcomes of FFR-Guided PCI in Patients With Coronary Artery Disease

Live From Denver: TCT 2017, Day Four

ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Trial Results Often Struggle to Keep Pace With Evolving Technology

Physiological Assessment in Multivessel Disease: What Will SYNTAX 2 and FAME 3 Tell Us?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content